Medicare Part D plans could switch the coverage status of a reference biologic midyear if the plan adds a biosimilar for that product to the formulary, under an amendment added to the Senate Finance Committee’s pharmacy benefit manager reform package, which cleared the committee on a 26-1 vote 26 July.
The amendment from Sens. Debbie Stabenow, D-MI, and James Lankford, R-OK, was added to the chairman’s mark of the Modernizing...







